SCHEMBL21873033

SCHEMBL21873033

CCN(CCCO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)c1ncc(-c2ccc(Cc3c[nH]c4ncccc34)c(C)n2)c(OC)n1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 5/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ AURKA O14965 2/20 0.35
▸ CDC7 O00311 3/20 0.34
▸ GPR84 Q9NQS5 2/20 0.34
▸ MET P08581 1/20 0.33
▸ FGFR1 P11362 1/20 0.33
▸ FGFR4 P22455 1/20 0.33
▸ CYP2C9 P11712 3/20 0.33
▸ MAP4K4 O95819 1/20 0.32
▸ PIM1 P11309 1/20 0.32
▸ PRKACA P17612 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ HIPK2 Q9H2X6 1/20 0.32
▸ CLK4 Q9HAZ1 1/20 0.32
▸ MKNK2 Q9HBH9 1/20 0.32
▸ IRAK4 Q9NWZ3 1/20 0.32
▸ DBF4 Q9UBU7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21873021 0.90 CYP2C9 (0.33) CYP3A4CYP2C19CYP2C9
SCHEMBL21873020 0.86 PDPK1 (0.40) MET
SCHEMBL21873103 0.86 CYP3A4 (0.41) CYP3A4CYP2C19AURKACDC7GPR84
SCHEMBL21873027 0.84 CYP3A4 (0.38) CYP3A4CYP2C19CYP2C9
SCHEMBL21873058 0.83 CYP3A4 (0.38) CYP3A4CYP2C19AURKACYP2C9
SCHEMBL21873014 0.83 AURKA (0.40) CYP3A4CYP2C19AURKACDC7GPR84
SCHEMBL21873088 0.79 PDPK1 (0.39) MET
SCHEMBL21906349 0.78 CYP2C9 (0.33) CYP3A4CYP2C9
SCHEMBL21873151 0.77 AURKA (0.43) CYP3A4CYP2C19AURKACDC7GPR84
SCHEMBL21872974 0.76 CYP2C9 (0.33) CYP3A4CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CSF1R, CSF3R, FSHR CYP3A4 2278/4885CYP2C19 1843/4885AURKA 3341/4885
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof CSF1R, CSF3R, FSHR CYP3A4 2278/4885CYP2C19 1843/4885AURKA 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback